Oncology-Inspired Treatment Options for COVID-19.
J Nucl Med
; 61(12): 1720-1723, 2020 12.
Article
em En
| MEDLINE
| ID: mdl-32680924
ABSTRACT
CR3022 is a human antibody that binds to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we explore the use of CR3022 as a molecularly targeted radiotherapeutic. Methods:
CR3022 was labeled with 131I and purified, yielding 131I-CR3022. Using a magnetic bead assay and a recombinant SARS-CoV-2 spike protein fragment, we tested binding of 131I-CR3022 in the presence and absence of CR3022.Results:
We conjugated the antibody CR3022 with a purity of more than 98% and a specific activity of more than 292 MBq/mg. Using a bead-based assay, we confirmed that binding of 131I-CR3022 is selective and is significantly reduced in the presence of unlabeled antibody (3.14% ± 0.14% specific uptake and 0.10% ± 0.01% specific uptake, respectively; P < 0.0001).Conclusion:
Our results confirm the potential of CR3022 as a molecularly targeted probe for SARS-CoV-2. A labeled version of CR3022 could potentially be used for Auger radiotherapy or noninvasive imaging.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
COVID-19
/
Anticorpos Monoclonais
Limite:
Humans
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article